KHK 2823

Drug Profile

KHK 2823

Alternative Names: Anti-CD123 fully human antibody; KHK2823

Latest Information Update: 25 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antineoplastics
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 25 Mar 2016 Phase-I development is ongoing in United Kingdom
  • 01 Jun 2014 Phase-I clinical trials in Acute myeloid leukaemia in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top